retatrutide clinical trial thailand ESC 2024: improves lipid and cardiovascular risk profile in Phase II Retatrutide Phase 3: TRIUMPH Program

Grade Study Research Group, Nathan DM, Lachin JM, Bebu I, Burch HB, Buse JB, Cherrington AL, Fortmann SP, Green JB, Kahn SE, Kirkman MS, Krause-Steinrauf H, Larkin ME, Phillips LS, Pop-Busui R, Steffes M, Tiktin M, Tripputi M, Wexler DJ, Younes N, The GSRG

This reduces the pleasure associated with high-calorie food consumption, helping to decrease overeating

DOI: 10.1056/NEJMoa1411892

Other studies showed no effect of exenatide for 13 weeks (108, 109) or liraglutide for 13 weeks (121)

Amylin receptor signaling in the nucleus accumbens negatively modulates mu-opioid-driven feeding

The visceral fat that wraps around organs is actually more metabolically active and responsive to the hormonal changes GLP-1 therapy creates